Richard Alan Rudick net worth and biography

Richard Rudick Biography and Net Worth

Director of Immunic

Dr. Richard Rudick is a Fellow of the American Academy of Neurology and served on the faculty of the Cleveland Clinic Foundation until 2014. While at the Cleveland Clinic, he was Director of the Mellen Center for Multiple Sclerosis Treatment and Research, Inaugural Chief Clinical Research Officer, Vice-Chair of the Cleveland Clinic Neuroscience Institute, and Co-Director of the city-wide Cleveland Clinical and Translational Science Collaborative. Between 2014 and 2020, Dr. Rudick served at Biogen as Director of the Value-Based Medicine Innovation Hub and Director of the Medical Evidence, Research and Innovation Unit. He has authored over 250 peer-reviewed publications in the neurology space, was Chair of the National Multiple Sclerosis Society Research Program Advisory Committee, and was a member of the Advisory Council to the National Center for Research Resources and the Director’s Council of Councils at the National Institutes of Health.

Dr. Rudick earned his medical degree from Case Western Reserve University School of Medicine, and completed clinical and research training at the University of Rochester.

Dr. Rudick has been a member of Immunic’s Board since April 2023. He serves on the Compensation Committee and the Nominating and Corporate Governance Committee.

What is Richard Alan Rudick's net worth?: The estimated net worth of Richard Alan Rudick is at least $843.32 thousand as of November 12th, 2024. Rudick owns 87,300 shares of Immunic stock worth more than $843,318 as of April 27th. This net worth approximation does not reflect any other assets that Rudick may own. Learn More about Richard Alan Rudick's net worth.
How do I contact Richard Alan Rudick?: The corporate mailing address for Rudick and other Immunic executives is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. Immunic can also be reached via phone at (332) 255-9818 and via email at [email protected]. Learn More on Richard Alan Rudick's contact information.
Has Richard Alan Rudick been buying or selling shares of Immunic?: Richard Alan Rudick has not been actively trading shares of Immunic in the last ninety days. Most recently, on Tuesday, November 12th, Richard Alan Rudick bought 87,300 shares of Immunic stock. The stock was acquired at an average cost of $1.15 per share, with a total value of $100,395.00. Following the completion of the transaction, the director now directly owns 87,300 shares of the company's stock, valued at $100,395. Learn More on Richard Alan Rudick's trading history.
Who are Immunic's active insiders?: Immunic's insider roster includes Duane Nash (Chairman), Richard Rudick (Director), Daniel Vitt (CEO), and Glenn Whaley (Insider). Learn More on Immunic's active insiders.
Are insiders buying or selling shares of Immunic?: In the last twelve months, Immunic insiders bought shares 2 times. They purchased a total of 35,000 shares worth more than $28,150.00. The most recent insider tranaction occured on June, 13th when Chairman Duane Nash bought 20,000 shares worth more than $16,600.00. Insiders at Immunic own 14.0% of the company. Learn More about insider trades at Immunic.
Information on this page was last updated on 6/13/2025.

Richard Alan Rudick Insider Trading History at Immunic

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/12/2024	Buy	87,300	$1.15	$100,395.00	87,300

Richard Alan Rudick Buying and Selling Activity at Immunic

Immunic Company Overview

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Today's Range

Now: $9.66

$8.50

$10.30

50 Day Range

MA: $1.10

$0.87

$1.45

2 Week Range

Now: $9.66

$5.06

$15.10

Volume

304,328 shs

Average Volume

341,214 shs

Market Capitalization

$1.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37